Welcome to our dedicated page for Plus Therapeutics SEC filings (Ticker: PSTV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Plus Therapeutics, Inc. (NASDAQ: PSTV) SEC filings page on Stock Titan brings together the company’s official regulatory disclosures, offering investors a structured view of its financial condition, capital structure, governance, and clinical-stage operations. As a clinical-stage pharmaceutical company focused on targeted radiotherapeutics and CNS cancer diagnostics, Plus Therapeutics uses SEC reports to describe its business, risks, and material events.
Core filings such as the Form 10-K annual report and Form 10-Q quarterly reports provide detailed discussions of the company’s radiotherapeutic pipeline, including REYOBIQ™ (rhenium Re186 obisbemeda), its CNSide Diagnostics subsidiary, grant funding, and liquidity. These documents also outline risk factors related to clinical development, regulatory approvals, Nasdaq listing standards, and capital needs.
Frequent Form 8-K current reports disclose material events, including Nasdaq notices about minimum bid price and stockholders’ equity compliance, extensions to regain listing compliance, purchase agreements with institutional investors, public offerings of common stock and warrants, and significant lease or financing arrangements. Proxy materials on Schedule 14A describe board elections, stock incentive plans, reverse stock split authority, and stockholder voting outcomes.
On this page, Stock Titan enhances access to these filings with AI-powered summaries that explain key points in plain language, helping users quickly understand complex documents such as registration statements on Form S-1, equity purchase agreements, or governance-related filings. Real-time integration with the SEC’s EDGAR system ensures new Plus Therapeutics filings appear promptly.
Investors can also use this section to monitor potential insider activity reported on ownership forms, as well as to follow any future proxy statements addressing compensation or capital structure changes. By combining raw filings with AI-generated highlights, the page is designed to make Plus Therapeutics’ regulatory history and ongoing disclosure record more accessible to both experienced and newer market participants.
Richard J. Hawkins, a director of Plus Therapeutics, Inc. (PSTV), reported receipt of a stock option grant on 08/13/2025. The award is a stock option with an exercise price of $0.5744 covering 397,794 underlying shares. Following the reported transaction, the reporting person beneficially owns 397,794 shares on a direct basis. The option vests monthly over 12 months from the grant date and will vest in full at the issuer's 2026 annual stockholder meeting, subject to continued service. The option has an expiration date shown as 08/12/2035. The Form 4 was signed by an attorney-in-fact, Andrew Sims, on 08/15/2025.
PLUS THERAPEUTICS, Inc. (PSTV) director Howard Clowes was reported as the recipient of a stock option grant. The Form 4 shows a grant of 297,794 stock options at an exercise price of $0.5744, with a transaction date of 08/13/2025.
The options vest monthly over 12 months from the grant date, and vest in full at the issuer's 2026 Annual Stockholder Meeting, subject to continued service. Following the reported transaction, the reporting person beneficially owns 297,794 shares/options on a direct basis.
Robert P. Lenk, a director of PLUS THERAPEUTICS, Inc. (PSTV), was granted stock options on 08/13/2025. The Form 4 reports acquisition of 297,794 stock options with an exercise price of $0.5744 per share. The filing states the options vest monthly over 12 months from the grant date and vest in full upon the issuer's 2026 Annual Stockholder Meeting, subject to continued service. The Form 4 shows the reporting person holds 297,794 underlying shares following the transaction and is filed by one reporting person. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Andrew John Hugh MacIntyre Sims, serving as Chief Financial Officer of PLUS THERAPEUTICS, Inc. (PSTV), reported equity awards granted on 08/13/2025. He received a stock option to purchase 1,379,636 shares at an exercise price of $0.5744 per share, exercisable through 08/12/2035, with the option vesting over four years in equal monthly 1/48th installments. He also received 459,878 restricted stock units (RSUs) that convert one-for-one into common stock upon vesting; the RSUs vest over three years with one-third vesting on the first anniversary and the remaining two-thirds vesting monthly over the next two years. The Form 4 was signed on 08/15/2025 and reports these grants as direct beneficial ownership following the transactions.
Reporting person: An van Es-Johansson, identified as a Director of PLUS THERAPEUTICS, Inc. (PSTV). Transaction: on 08/13/2025 the reporting person was granted 297,794 stock options with an exercise price of $0.5744. The options vest monthly over 12 months from the grant date in substantially equal installments and vest in full at the issuer's 2026 annual stockholder meeting if the reporting person remains in service. The options expire on 08/12/2035 and the report shows 297,794 underlying common shares beneficially owned following the transaction in a direct ownership form. The Form 4 was signed by an attorney-in-fact.
PLUS THERAPEUTICS, Inc. (PSTV) Form 3 shows an initial Section 16 filing by Kyle Guse dated 04/18/2025 listing his role as a Director and providing a company address in Austin, TX. The filing reports 0 shares of Common Stock owned directly and discloses no derivative securities. The form is signed by an attorney-in-fact on 08/15/2025.
Plus Therapeutics, Inc. Schedule 13G/A filed by S.H.N. Financial Investments Ltd. reports beneficial ownership of 1,500,000 shares of common stock, representing 1.51% of the class based on 99,264,526 shares outstanding. The amendment references a prior Schedule 13G filed March 18, 2025, which covered 1,209,754 shares purchased March 4, 2025, indicating the reporter increased its position to the 1.5 million share level.
The filer is S.H.N. Financial Investments Ltd., organized in Israel, with Nir Shamir identified as CEO of the reporting entity and noted as potentially deemed to beneficially own the reported shares, though he disclaims ownership for other purposes. The filing certifies the shares were not acquired to influence control of the issuer.
Plus Therapeutics reported that Nasdaq's Listing Qualifications Department found it did not meet the minimum stockholders' equity requirement after the company reported a stockholders' deficit of ($23,641,000) for the period ended March 31, 2025. The Staff initially determined to delist the company's securities, and the company timely requested a hearing.
A Nasdaq Hearings Panel granted continued listing subject to two conditions: demonstrate compliance with the $2.5 million equity requirement by August 14, 2025 through a public filing describing transactions and indicating post-transaction equity (optionally including a balance sheet not older than 60 days with pro forma adjustments), and have the closing bid price meet or exceed $1.00 per share for 10 consecutive business days by September 8, 2025.
Plus Therapeutics reported the results of its August 7, 2025 annual meeting. Of 60,490,101 shares outstanding at the June 18, 2025 record date, 29,973,272 shares were represented, constituting a quorum. All director nominees listed in the proxy were elected, with individual "for" votes generally in the range of 18.7 million to 18.94 million and 10,294,600 broker non-votes recorded for those director elections.
Stockholders approved several material proposals: authorization to potentially issue up to $50.0 million of common stock (plus up to $1.0 million as a commitment fee) to Lincoln Park Capital under the June 17, 2025 purchase agreement; discretionary authority for the board to effect a reverse stock split at any ratio between 1-for-2 and 1-for-250; an advisory approval of named executive officer compensation; and the fifth amendment and restatement of the 2020 Stock Incentive Plan.
Plus Therapeutics (PSTV) filed a registration statement to register up to 33,000,000 shares for resale by Lincoln Park Capital Fund under a purchase agreement that can provide up to $50.0 million of aggregate gross proceeds (an initial $25.0 million available amount with an automatic additional $25.0 million upon satisfaction of conditions). The company has received approximately $2.8 million to date and intends to issue 1,612,903 Initial Commitment Shares valued at $0.31 as part of the commitment fee. The filing shows 99,264,526 shares outstanding and a pro forma 132,264,526 if all registered shares are issued, and highlights potential dilution, dependence on Lincoln Park as a financing source, a disclosed Make-Whole Repayment obligation of approximately $17.3 million, and that any proceeds would be used for working capital, general corporate purposes and, if required, repayment obligations.